Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984998740> ?p ?o ?g. }
- W2984998740 endingPage "21" @default.
- W2984998740 startingPage "9" @default.
- W2984998740 abstract "Abiraterone and enzalutamide are recently-approved androgen deprivation therapies (ADTs) for metastatic prostate cancer, with unknown cardiac safety profiles. Abiraterone has a propensity to hypermineralocorticism on top of androgen deprivation, so might carry an additional risk for atrial tachyarrhythmia (AT) and heart failure (HF) compared with other ADTs. To determine if abiraterone was associated with an increased proportion of AT and HF reports among all suspected adverse drug reactions (ADRs) reported in several pharmacovigilance databases compared with enzalutamide, other ADTs and all other drugs. In this observational retrospective pharmacovigilance study, we performed a disproportionality analysis of reports of suspected ADRs in men in the French pharmacovigilance database, the European pharmacovigilance database and the international pharmacovigilance database VigiBase, to evaluate the reporting odds ratios (RORs) of AT and HF for abiraterone compared with enzalutamide, other ADTs and all other drugs. In the 5,759,781 ADR reports in men in VigiBase, 55,070 pertained to ADTs. The RORs for AT for abiraterone versus enzalutamide, other ADTs and all other drugs were 4.1 (95% confidence interval 3.1–5.3), 3.7 (3–4.5) and 3.2 (2.7–3.7), respectively (P < 0.0001 for all). The corresponding RORs for HF were 2.5 (2–3), 1.5 (1.3–1.7) and 2 (1.7–2.3), respectively (P < 0.0001 for all). These results were concordant with the French and European pharmacovigilance databases. Mean times to AT and HF onset were shorter with abiraterone (5.2 ± 0.8 and 4.5 ± 0.6 months, respectively) versus other ADTs (13.3 ± 3.2 and 9.2 ± 1.1 months, respectively) (both P < 0.05). Cases on abiraterone versus other ADTs were more frequently associated with at least two ADR terms, including AT, HF, hypokalaemia, hypertension and oedema (13.6% vs 6%; P < 0.0001). For abiraterone, age, but not dose, was associated with reporting of AT and HF versus any other ADR. Compared with other ADTs, abiraterone was associated with higher reporting of AT and HF, associated with hypokalaemia, hypertension and oedema. These findings are consistent with the hypermineralocorticism induced by abiraterone, but not by other ADTs. L’abiratérone et l’enzalutamide sont deux traitements anti-androgènes (AA) utilisés dans le traitement des cancers prostatiques métastatiques. Leur profil de tolérance cardiovasculaire est peu connu. L’abiratérone est responsable d’un hyper-minéralocorticisme, qui pourrait entraîner un risque supplémentaire de tachyarythmie supraventriculaire (TSV) et d’insuffisance cardiaque (IC). Étudier s’il existe une disproportionnalité du nombre de cas rapportés de TSV et d’IC par rapport aux taux globaux d’évènements indésirables (EI) chez les patients traités par abiratérone versus (vs) enzalutamide, vs les autres AA et vs l’ensemble des médicaments de la base. Étude observationnelle, rétrospective, de disproportionnalité avec calcul du reporting odds-ratio (ROR), dans les bases de pharmacovigilance française, européenne et mondiale (VigiBase). Parmi les 5 759 781 EI déclarés chez des hommes dans VigiBase, 55 070 concernaient les médicaments AA étudiés. Le ROR pour les TSV associées à l’abiratérone était de 3,2 [2,7–3,7] vs enzalutamide, de 3,7 [3–4,5] vs les autres AA et de 3,2 [2,7–3,7] vs l’ensemble de la base (p < 0,0001 pour tous). Le ROR pour les IC était de 2,5 [2–3], de 1,5 [1,3–1,7] et de 2 [1,7–2,3], respectivement (p < 0,0001 pour tous). Les délais moyens d’apparition des TSV et des IC étaient plus court pour l’abiratérone (5,2 ± 0,8 et 4,5 ± 0,6 mois, respectivement) que pour les autres AA (13,3 ± 3,2 et 9,2 ± 1,1 mois ; p < 0,05). Par rapport aux autres AA, les EI déclarés avec l’abiratérone comprenaient plus fréquemment ≥ 2 EI à type de TSV, IC, hypokaliémie, hypertension et œdème (13,6 % vs 6 %, p < 0,0001). L’abiratérone, responsable d’un hyper-minéralocorticisme, présente une proportion plus élevée de cas rapportés de TSV et d’IC, fréquemment associés à l’hypokaliémie, l’hypertension ou les œdèmes, comparé à l’enzalutamide et aux autres AA dans les bases de pharmacovigilance française, européenne et mondiale." @default.
- W2984998740 created "2019-11-22" @default.
- W2984998740 creator A5006475937 @default.
- W2984998740 creator A5008481350 @default.
- W2984998740 creator A5009328116 @default.
- W2984998740 creator A5010670616 @default.
- W2984998740 creator A5019401898 @default.
- W2984998740 creator A5027731973 @default.
- W2984998740 creator A5058141203 @default.
- W2984998740 creator A5063177685 @default.
- W2984998740 creator A5064241453 @default.
- W2984998740 creator A5064378838 @default.
- W2984998740 creator A5086895898 @default.
- W2984998740 date "2020-01-01" @default.
- W2984998740 modified "2023-10-07" @default.
- W2984998740 title "Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study" @default.
- W2984998740 cites W1584828549 @default.
- W2984998740 cites W1909369860 @default.
- W2984998740 cites W1977362120 @default.
- W2984998740 cites W2028402045 @default.
- W2984998740 cites W2030172654 @default.
- W2984998740 cites W2037072711 @default.
- W2984998740 cites W2037750383 @default.
- W2984998740 cites W2038201411 @default.
- W2984998740 cites W2055346449 @default.
- W2984998740 cites W2064854697 @default.
- W2984998740 cites W2078222208 @default.
- W2984998740 cites W2086049425 @default.
- W2984998740 cites W2093954073 @default.
- W2984998740 cites W2100074173 @default.
- W2984998740 cites W2102136926 @default.
- W2984998740 cites W2110534364 @default.
- W2984998740 cites W2131170102 @default.
- W2984998740 cites W2137467802 @default.
- W2984998740 cites W2138354036 @default.
- W2984998740 cites W2140742150 @default.
- W2984998740 cites W2141068637 @default.
- W2984998740 cites W2144851822 @default.
- W2984998740 cites W2148643283 @default.
- W2984998740 cites W2152641996 @default.
- W2984998740 cites W2156497356 @default.
- W2984998740 cites W2158299492 @default.
- W2984998740 cites W2164705414 @default.
- W2984998740 cites W2167186282 @default.
- W2984998740 cites W2168108459 @default.
- W2984998740 cites W2170544517 @default.
- W2984998740 cites W2199999556 @default.
- W2984998740 cites W2269768367 @default.
- W2984998740 cites W2286563710 @default.
- W2984998740 cites W2325205130 @default.
- W2984998740 cites W2365223954 @default.
- W2984998740 cites W2486747697 @default.
- W2984998740 cites W2559290083 @default.
- W2984998740 cites W2566454068 @default.
- W2984998740 cites W2591646795 @default.
- W2984998740 cites W2620746860 @default.
- W2984998740 cites W2620798309 @default.
- W2984998740 cites W2743936472 @default.
- W2984998740 cites W2747347785 @default.
- W2984998740 cites W2775324632 @default.
- W2984998740 cites W2801142990 @default.
- W2984998740 cites W2801879399 @default.
- W2984998740 cites W2811353210 @default.
- W2984998740 cites W2887268579 @default.
- W2984998740 cites W2914436218 @default.
- W2984998740 cites W2971331806 @default.
- W2984998740 cites W2975521664 @default.
- W2984998740 cites W64014791 @default.
- W2984998740 doi "https://doi.org/10.1016/j.acvd.2019.09.006" @default.
- W2984998740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31685432" @default.
- W2984998740 hasPublicationYear "2020" @default.
- W2984998740 type Work @default.
- W2984998740 sameAs 2984998740 @default.
- W2984998740 citedByCount "23" @default.
- W2984998740 countsByYear W29849987402020 @default.
- W2984998740 countsByYear W29849987402021 @default.
- W2984998740 countsByYear W29849987402022 @default.
- W2984998740 countsByYear W29849987402023 @default.
- W2984998740 crossrefType "journal-article" @default.
- W2984998740 hasAuthorship W2984998740A5006475937 @default.
- W2984998740 hasAuthorship W2984998740A5008481350 @default.
- W2984998740 hasAuthorship W2984998740A5009328116 @default.
- W2984998740 hasAuthorship W2984998740A5010670616 @default.
- W2984998740 hasAuthorship W2984998740A5019401898 @default.
- W2984998740 hasAuthorship W2984998740A5027731973 @default.
- W2984998740 hasAuthorship W2984998740A5058141203 @default.
- W2984998740 hasAuthorship W2984998740A5063177685 @default.
- W2984998740 hasAuthorship W2984998740A5064241453 @default.
- W2984998740 hasAuthorship W2984998740A5064378838 @default.
- W2984998740 hasAuthorship W2984998740A5086895898 @default.
- W2984998740 hasBestOaLocation W29849987401 @default.
- W2984998740 hasConcept C121608353 @default.
- W2984998740 hasConcept C126322002 @default.
- W2984998740 hasConcept C197934379 @default.
- W2984998740 hasConcept C2776421732 @default.
- W2984998740 hasConcept C2776551883 @default.
- W2984998740 hasConcept C2778198053 @default.
- W2984998740 hasConcept C2780192828 @default.